Adbry

Generic name: Tralokinumab-ldrm
Dosage form: Prefilled syringe for subcutaneous injection
Drug class: Interleukin inhibitors

Usage of Adbry

Adbry (tralokinumab-ldrm) is an interleukin-13 (IL-13) inhibitor that may be used to treat adults and children aged 12 years and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with other topical prescription treatments or those treatments are not advised. Adbry can be used with or without topical corticosteroids and it is self-administered by subcutaneous (under the skin) injection every other week after an initial loading dose.

Adbry works by specifically targeting IL-13, which is a protein that research has shown contributes to skin inflammation in eczema. Adbry binds to IL-13, preventing it from interacting with its receptor and releasing proinflammatory cytokines, chemokines, and IgE.

Adbry was FDA approved on December 27, 2021.

Adbry side effects

Adbry can cause serious side effects, including:

Allergic reactions (hypersensitivity), including a severe reaction known as anaphylaxis. Stop using Adbry and tell your healthcare provider or get emergency help right away if you get any of the following symptoms:

breathing problems

swelling of the face, mouth, and tongue

hives

itching

fainting, dizziness, feeling lightheaded (low blood pressure)

skin rash.

Eye problems. Tell your healthcare provider if you have any worsening eye problems, including eye pain or vision changes.

The most common side effects affecting 1% or more people include:

upper respiratory tract infections

eye and eyelid inflammation, including redness, swelling, and itching

injection site reactions

high laboratory counts of a certain white blood cell (eosinophilia).

These are not all of the possible side effects. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Before taking Adbry

Before using Adbry, tell your healthcare provider about all your medical conditions, including if you:

have eye problems

have a parasitic (helminth) infection

are scheduled to receive any vaccinations. You should not receive a live vaccine if you are treated with Adbry

are pregnant or plan to become pregnant

are breastfeeding or plan to breastfeed.

Pregnancy

It is not known whether Adbry will harm your unborn baby. There is a pregnancy exposure registry for women who use Adbry during pregnancy. You or your healthcare provider can get information and enroll you in this registry by calling 1-877-311-8972 or visiting https://mothertobaby.org/ongoing-study/adbry-tralokinumab/.

Breastfeeding

It is not known whether Adbry passes into your breast milk and if it can harm an unborn baby. Talk to your doctor if you are breastfeeding.

Relate drugs

How to use Adbry

Adults 18 years and older

Administer an initial loading dose of 600mg (given as four Adbry 150mg injections at different injection sites on the same day).

The usual maintenance dose is 300 mg (two 150 mg injections given at different injection sites) administered every other week. A dosage of 300 mg every 4 weeks may be considered for patients below 100 kg who achieve clear or almost clear skin after 16 weeks of treatment.

Children aged 12 through 17 years

Administer an initial loading dose of 300mg (given as two Adbry 150mg injections at different injection sites on the same day).

The usual maintenance dose is 150 mg (one 150 mg injection) administered every other week.

Warnings

Hypersensitivity reactions, including anaphylaxis, and angioedema have occurred after administration of Adbry. Do not use Adbry if you are allergic to tralokinumab or any of the ingredients. Stop taking Adbry and call your doctor immediately if you develop an allergic reaction.

May cause eye problems such as conjunctivitis (an inflammation of the membrane that lines the eyelid and eyeball) or keratitis (corneal ulcer). Report new onset or worsening eye symptoms to your healthcare provider.

Patients with a pre-existing helminth (parasitic worm) infection should be treated before starting Adbry. If a patient becomes infected during treatment and does not respond to anti-parasitic treatment, your healthcare provider may temporarily stop treatment until the infection resolves.

Avoid vaccination with live vaccines during treatment with Adbry.

What other drugs will affect Adbry

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

See the product information for a full list of interactions.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.